Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;15(2):143-150.
doi: 10.5114/aic.2019.86009. Epub 2019 Jun 26.

Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study

Affiliations

Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study

Tomasz Roleder et al. Postepy Kardiol Interwencyjnej. 2019.

Abstract

Introduction: To date the early strut coverage with the second-generation durable-polymer ONYX zotarolimus-eluting stent (O-ZES) is unknown.

Aim: Optical coherence tomography (OCT) assessed the strut coverage of O-ZES at thirty-day follow-up.

Material and methods: OCT was performed after implantation and at 1-month follow-up in 15 patients treated with O-ZES.

Results: Mean patient age was 67 ±7 years (73% males). The clinical presentation consisted of acute coronary syndromes (n = 13) and stable coronary disease (n = 2). Four (26%) patients had diabetes. OCT analysis was performed at baseline and 1-month follow-up in all stents. 378 cross-sections with 3582 struts were assessed at baseline and 3661 at follow-up. At follow-up, 88% struts were covered by tissue with a median thickness 37.91 μm (IQR: 22.32-64.15). Median in-stent area obstruction by neointima was 2.64% (IQR: 1.70-4.84). From the total stent covered area, 92.3% showed complete strut coverage. Homogeneous tissue was observed in 74% of cases. There were no differences in minimal lumen area (5.07 ±1.08 mm2 vs. 4.81 ±0.94 mm2, p = 0.125) or minimal stent area (4.95 ±1.22 mm2 vs. 4.92 ±0.99 mm2) at baseline and at follow-up. There were no differences in the rate of strut malapposition (4.3% vs. 5.7%, p = 0.417). For all stents, malapposition volume was 47.9 mm3 at baseline and 51.7 mm3 at follow-up, giving the late acquired stent malapposition volume of 3.8 mm3.

Conclusions: The second-generation durable polymer O-ZES showed favorable vessel healing at 30-day OCT follow-up.

Keywords: 1-month follow-up; optical coherence tomography; vessel healing; zotarolimus-eluting stent.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative OCT images of O-ZES coverage at 30-day follow-up. A, C – Baseline cross-sectional images of the implanted study stent. B – Cross-sectional image of study stent covered with homogeneous neointima. D – Cross-sectional image of study stent covered with heterogeneous neointima
Figure 2
Figure 2
Representative images of O-ZES surface area analysis. A – Cross-sectional image of the implanted stent. B – Boxes indicate the 1 mm intervals of surface measurements. Red color indicates covered struts, other color indicates uncovered struts. C, D, E – Representative images of study stent with lumen surface (white line) covered with uncovered struts (blue boxes)
Figure 3
Figure 3
The proportion of neointimal thickness measured for a single strut

Similar articles

Cited by

References

    1. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500–10. - PubMed
    1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–48. - PubMed
    1. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371–82. - PubMed
    1. Zhang Y, Tian N, Dong S, et al. Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. Chin Med J (Engl) 2014;127:2159–66. - PubMed
    1. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–47. - PubMed